Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus FLOT perioperative chemotherapy versus FLOT alone for stage III resectable advanced gastric cancer
ChiCTR-IIR-17012911Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jan 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib, fluorouracil, folinic acid, oxaliplatin and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Resection rate, Pathologic complete response and 1 more. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
Rivoceranibfluorouracilfolinic acidoxaliplatindocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-IIR-17012911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012911.